March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
Methylene blue helps hair growth by protecting hair stem cells from stress.
February 2026 in “Editora Pasteur eBooks” A comprehensive, personalized approach is needed for treating female pattern hair loss and obesity, involving multiple medical disciplines and lifestyle changes.
January 2026 in “Quality in Sport” Semaglutide may help some skin disorders but can also cause skin issues.
A rash from semaglutide may be due to propylene glycol, not the drug itself.
October 2025 in “Brazilian Journal of Hair Health” Hair loss from weight-loss treatments is usually temporary and reversible.
May 2025 in “International Journal of Women’s Dermatology” 5-alpha reductase inhibitors and spironolactone don't increase gynecological tumor risk, glucagon-like-peptide-1 receptor agonists may increase alopecia risk, sanitary pads can cause dermatitis, early hidradenitis suppurativa intervention is crucial for Hispanic patients, community education boosts skin cancer awareness, metformin may improve skin cancer survival, LNG-IUDs can increase acne risk, machine learning accurately detects basal cell carcinoma, JAK-inhibitors may raise miscarriage risk, inclusive skincare ads affect those with darker skin, and CCCA in Black women might involve autoimmunity.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
February 2025 in “Journal of Neonatal Surgery” Combining antidiabetic drugs, hormonal therapies, and lifestyle changes can improve health in women with PCOS.
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Newer GLP-1 drugs like semaglutide may cause hair loss.
December 2024 in “Cureus” Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
December 2024 in “African Journal of Biomedical Research” Combining lifestyle changes and medication is most effective for managing PCOS symptoms.
August 2024 in “International Journal of Dermatology” New therapies and treatments for hair disorders, especially in curly hair, show promise.
May 2024 in “Psychiatric News” Weight-loss drugs are not linked to suicidal thoughts.
Early detection and comprehensive treatment of PCOS are crucial due to its long-term health impacts and associated risks.
Women with Polycystic Ovary Syndrome (PCOS) have a higher risk of developing type 2 diabetes due to insulin resistance.
December 2019 in “Orvostudományi Értesítö” Lifestyle changes, medications, and fertility treatments can improve PCOS symptoms and prevent complications.
March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
2 citations
,
January 2025 in “Cutis” Glycemic control medications for Type 2 diabetes can affect skin conditions like psoriasis.
1 citations
,
February 2025 in “Frontiers in Nutrition” Hawthorn-probiotic postbiotic may relieve constipation in elderly.
Individualized treatments may help manage Dercum's disease symptoms.
July 2024 in “Journal of Investigative Dermatology” JW0061 may be a new treatment for hair loss by promoting hair growth through WNT signaling.
May 2024 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in patient education and personalized care.
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
25 citations
,
September 2024 in “Cardiovascular Drugs and Therapy” GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
31 citations
,
October 2010 in “Progress in lipid research” LPA3 is crucial for embryo implantation and links LPA to prostaglandin signaling.
3 citations
,
December 2023 in “International Journal of Nanomedicine” Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.
58 citations
,
February 2013 in “Journal of Biological Chemistry” LGR5 mainly stays inside cells, moving to the trans-Golgi network, and this process is important for its role in cell signaling.
September 2025 in “Genes & Diseases” Lgr6+ cells are important for tissue repair and could be a target for treating cancer and other diseases.